Tecentriq, Cabometyx May Not Improve Survival Over Chemo in NSCLC

Tecentriq plus Cabometyx conferred no overall survival benefit when compared with chemotherapy, a study showed.

Related Keywords

Joel Neal ,Division Of Oncology At Stanford University ,National Cancer Institute ,